title: Amantadine: a review of use in child and adolescent psychiatry.
abstract: OBJECTIVE
  To review published literature regarding the pharmacology and use of amantadine in child and adolescent psychiatry.
  
  
  METHODS
  A LITERATURE SEARCH OF SEVERAL DATABASES (PUBMED, PSYCHINFO, CINAHL, MEDLINE, PSYCARTICLES, BIOMEDICAL REFERENCE COLLECTION AND ACADEMIS SEARCH COMPLETE) WAS CONDUCTED WITH THE SEARCH TERMS: 'amantadine' with limits: English language, Human trials, all child (aged 0-18 years). The search was later expanded to include 'Adults' and additional relevant articles were selected from reference lists.
  
  
  RESULTS
  The psychotropic effect of amantadine is related to its antagonism of the N-methyl-D-aspartate (NMDA) receptor. It decreases the toxic effects of the glutamatergic neurotransmitter system which plays an important role in many psychiatric disorders. Two randomized controlled trials (RCTs) of amantadine were identified in children and adolescents. One reported beneficial effects in controlling the symptoms of irritability and hyperactivity in autistic disorder and the other described a significant impact in attention deficit hyperactivity disorder (ADHD). Two open label studies also reported positive effects in ADHD. A pilot study in children with enuresis reported significant reduction in wetting frequency. Studies in adults, with relevance to children and adolescents, reported effectiveness in resistant depression, obsessive compulsive disorder and in counteracting side effects of some psychotropic medications. RCTs found in traumatic brain injury indicated a neuroprotective effect and effectiveness in controlling agitation and aggression. Amantadine is well tolerated in children and adolescents, with an acceptable side effect profile, and considered safe for long term use.
  
  
  CONCLUSIONS
  Amantadine shows potential for use as a safe alternative or as an augmenting agent for treating children with neuropsychiatric and various other disorders. Available data for such use, although promising, require further confirmation.
authors: Department of Psychiatry, Royal Inland Hospital, Kamloops, British Columbia.
authors: Sheik
authors: S
authors: Hosenbocus
authors: Raj
authors: R
authors: Chahal
keywords: N-methyl-D-aspartate receptor; amantadine; glutamatergic system; pharmacology
references: J Clin Psychiatry. 1989 Apr;50(4):143-4
references: 2564388
references: J Neural Transm Suppl. 1994;43:91-104
references: 7884411
references: J Neural Transm (Vienna). 1998;105(4-5):525-35
references: 9720980
references: Can J Psychiatry. 1986 Nov;31(8):757-8
references: 3791133
references: J Child Adolesc Psychopharmacol. 2007 Oct;17(5):657-64
references: 17979585
references: Eur Neuropsychopharmacol. 2001 Apr;11(2):181-2
references: 11313165
references: Psychosomatics. 2004 May-Jun;45(3):205-9
references: 15123844
references: J Clin Psychopharmacol. 1995 Feb;15(1):83-4
references: 7714234
references: J Am Acad Child Adolesc Psychiatry. 1997 Mar;36(3):301-2
references: 9055505
references: Int Clin Psychopharmacol. 2003 Mar;18(2):93-6
references: 12598820
references: Hum Psychopharmacol. 2011 Jan;26(1):86-7; author reply 88
references: 23055417
references: Neuropsychopharmacology. 2010 Jun;35(7):1520-30
references: 20336059
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1362-74
references: 18262702
references: J Clin Psychopharmacol. 1981 Jan;1(1):2-7
references: 6117579
references: Am J Phys Med Rehabil. 2004 Dec;83(12):893-7
references: 15624567
references: J Clin Psychopharmacol. 1984 Aug;4(4):223-5
references: 6470197
references: Brain Res Rev. 2009 Oct;61(2):105-23
references: 19481572
references: Clin Neuropharmacol. 2007 May-Jun;30(3):136-44
references: 17545748
references: J Child Adolesc Psychopharmacol. 2002 Fall;12(3):249-57
references: 12427299
references: Brain Res. 1994 Oct 31;662(1-2):255-8
references: 7859080
references: Am J Psychiatry. 2005 Sep;162(9):1744-6
references: 16135638
references: J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):654-7
references: 11392342
references: Hum Psychopharmacol. 2010 Nov;25(7-8):560-5
references: 21312290
references: J Can Acad Child Adolesc Psychiatry. 2012 May;21(2):130-46
references: 22548111
references: Clin Pharmacol Ther. 1979 Dec;26(6):729-36
references: 498714
references: Braz J Psychiatry. 2010 Dec;32(4):467-9
references: 21308277
references: Psychopharmacol Bull. 1980 Jul;16(3):67-9
references: 7403410
references: J Clin Psychopharmacol. 2010 Feb;30(1):85-6
references: 20075660
references: Psychiatry Clin Neurosci. 2004 Apr;58(2):163-7
references: 15009821
references: J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):658-65
references: 11392343
references: J Neurosci. 2005 Mar 30;25(13):3312-22
references: 15800186
references: Brain Inj. 1988 Oct-Dec;2(4):309-11
references: 3203176
references: Pharmacol Rep. 2007 Nov-Dec;59(6):778-84
references: 18195470
references: N Engl J Med. 2012 Mar 1;366(9):819-26
references: 22375973
references: J Clin Psychopharmacol. 1987 Apr;7(2):91-5
references: 2884239